Market capitalization | $217.55m |
Enterprise Value | $1.24b |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
P/B ratio (TTM) P/B ratio | negative |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-156.32m |
Free Cash Flow (TTM) Free Cash Flow | $-133.14m |
Cash position | $406.81m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
6 Analysts have issued a Prokidney forecast:
6 Analysts have issued a Prokidney forecast:
Sep '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | -4.03 -4.03 |
22%
22%
|
|
EBITDA | -152 -152 |
1%
1%
|
EBIT (Operating Income) EBIT | -156 -156 |
1%
1%
|
Net Profit | -46 -46 |
26%
26%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
ProKidney Corp. is a clinical-stage biotechnology company, which engages in the development of a proprietary cell therapy platform. The firm focuses on the treatment of chronic kidney disease (CKD), shifting the emphasis away from management of kidney failure, to the restoration of kidney function to stop or delay progression of CKD. It offers REACT, a product candidate that includes selected renal cells (SRCs) prepared from a patient's own, autologous, renal cells. The company is headquartered in Winston-Salem, NC.
Head office | Cayman Islands |
CEO | Bruce Culleton |
Employees | 163 |
Founded | 2015 |
Website | www.prokidney.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.